166 related articles for article (PubMed ID: 27189008)
21. Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?
von Minckwitz G; Fontanella C
Breast; 2013 Aug; 22 Suppl 2():S149-51. PubMed ID: 24074777
[TBL] [Abstract][Full Text] [Related]
22. Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study).
Takada M; Ishiguro H; Nagai S; Ohtani S; Kawabata H; Yanagita Y; Hozumi Y; Shimizu C; Takao S; Sato N; Kosaka Y; Sagara Y; Iwata H; Ohno S; Kuroi K; Masuda N; Yamashiro H; Sugimoto M; Kondo M; Naito Y; Sasano H; Inamoto T; Morita S; Toi M
Breast Cancer Res Treat; 2014 May; 145(1):143-53. PubMed ID: 24682674
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
24. Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy.
Promberger R; Dubsky P; Mittlböck M; Ott J; Singer C; Seemann R; Exner R; Panhofer P; Steger G; Bergen E; Gnant M; Jakesz R; Bago-Horvath Z; Rudas M; Bartsch R
Clin Breast Cancer; 2015 Dec; 15(6):505-11. PubMed ID: 26195436
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
26. [Predictive values of pathologic complete response for patient outcome in different molecular subtypes of breast cancer].
Liu W; Li JB; Wang T; Bian L; Zhang SH; Zhang HQ; Zhou JM; Song ST; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2016 Sep; 96(36):2898-2902. PubMed ID: 27760635
[No Abstract] [Full Text] [Related]
27. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
28. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
[TBL] [Abstract][Full Text] [Related]
29. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials.
Werutsky G; Untch M; Hanusch C; Fasching PA; Blohmer JU; Seiler S; Denkert C; Tesch H; Jackisch C; Gerber B; Schneeweiss A; Link T; Krug D; Huober J; Rhiem K; Kühn T; Vladimirova V; Nekljudova V; Loibl S
Eur J Cancer; 2020 May; 130():92-101. PubMed ID: 32179450
[TBL] [Abstract][Full Text] [Related]
30. Lessons from the neoadjuvant setting on how best to choose adjuvant therapies.
von Minckwitz G; Loibl S; Maisch A; Untch M
Breast; 2011 Oct; 20 Suppl 3():S142-5. PubMed ID: 22015282
[TBL] [Abstract][Full Text] [Related]
31. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
32. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
33. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.
Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G
Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797
[TBL] [Abstract][Full Text] [Related]
34. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
[TBL] [Abstract][Full Text] [Related]
35. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
37. HER2 as a predictive factor for successful neoadjuvant anthracycline chemotherapy of locally advanced and early breast cancer.
Wang J; Xu B; Yuan P; Li Q; Zhang P; Cai R; Ma F; Fan Y; Luo Y
Int J Biol Markers; 2014 Sep; 29(3):e187-92. PubMed ID: 25041784
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
[TBL] [Abstract][Full Text] [Related]
39. Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome.
Lim SK; Lee MH; Park IH; You JY; Nam BH; Kim BN; Ro J; Lee KS; Jung SY; Kwon YM; Lee ES
Cancer Res Treat; 2016 Jan; 48(1):133-41. PubMed ID: 25865655
[TBL] [Abstract][Full Text] [Related]
40. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis.
LeVasseur N; Sun J; Gondara L; Diocee R; Speers C; Lohrisch C; Chia S
J Cancer Res Clin Oncol; 2020 Feb; 146(2):529-536. PubMed ID: 31741041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
